Explainer

What Is the Best Medicine for Anxiety? What Trial Rankings Show

No single medicine is best for anxiety. A 2019 review of 89 trials found duloxetine, pregabalin, venlafaxine and escitalopram paired benefit with tolerability.

Mental Health Stats Research Team 7 min read

Key Takeaways

  • No single drug ranks best on every measure: in a 2019 network meta-analysis of 89 trials and 25,441 adults with generalized anxiety disorder, duloxetine, pregabalin, venlafaxine and escitalopram beat placebo with relatively good acceptability[1].89 trials[1]
  • For panic disorder, a 2022 BMJ review of 87 studies found SSRIs gave high remission with a low risk of adverse events, with sertraline and escitalopram standing out[2].87 studies[2]
  • Benzodiazepines ranked first for panic remission (SUCRA 84.5%) but carried 1.76 times the adverse-event risk of placebo[2], and the FDA has required a boxed warning on addiction, dependence and withdrawal since 2020[3].84.5%[2]
  • In social anxiety disorder, SSRIs and SNRIs were the only drug class to outperform pill placebo across 101 trials (standardized mean difference −0.44)[4].101 trials[4]
  • Adding psychotherapy to an antidepressant beat the antidepressant alone across 52 trials (Hedges' g 0.43, number needed to treat 4.2)[5].g = 0.43[5]
  • Among people who had responded to an antidepressant, 36.4% relapsed within up to a year after switching to placebo, compared with 16.4% who kept taking it[6].36.4%[6]
How "best" is measured: Anxiety drug trials usually score improvement on the Hamilton Anxiety Rating Scale (HAM-A) and measure acceptability as the share of people who stop treatment for any reason[1]. Network meta-analyses rank drugs by combining direct and indirect comparisons, so a top rank reflects average results in short trials, not how any one person will respond. In the 2022 panic disorder review, 86 of 87 studies had some concern or a high risk of bias[2].

What Is the Best Medicine for Anxiety? The Short Answer

There is no single best medicine for anxiety. In the largest comparisons of drug trials, the SSRI and SNRI antidepressants, especially escitalopram, duloxetine, venlafaxine and sertraline, come out ahead most often when benefit and tolerability are weighed together[1][2].

The answer shifts with the type of anxiety disorder, with what counts as "best" (largest symptom drop, fewest dropouts, fastest relief or lowest relapse) and with a person's other health conditions. This article covers how the large reviews rank the options; drug names, classes and FDA-approved uses are listed in our anxiety medication guide.

The biggest single review for generalized anxiety disorder (GAD), published in The Lancet in 2019, pooled 89 trials in which 25,441 patients were randomly assigned to 22 drugs or placebo[1]. Its authors concluded there are "several effective treatment choices" across drug classes[1].

How many Americans take these drugs, and which ones, is tracked separately in our anxiety medication statistics.

Acceptability (in drug trials)

In anxiety drug trials, acceptability is usually measured as the proportion of participants who stop treatment for any cause before the study ends[1]. It folds side effects, lack of benefit and other reasons for quitting into one number, which is why a drug can rank high on symptom reduction and low on acceptability.

Related Terms

tolerability
all-cause discontinuation
network meta-analysis
HAM-A

Source: Slee et al., The Lancet, 2019

How the Largest Trial Rankings Compare

In the 2019 Lancet analysis, four drugs combined a clear benefit over placebo with relatively good acceptability: duloxetine (HAM-A mean difference −3.13), pregabalin (−2.79), venlafaxine (−2.69) and escitalopram (−2.45)[1].

Quetiapine, an antipsychotic, produced the largest drop on the HAM-A (−3.60) but was poorly tolerated, with 1.44 times the odds of dropping out compared with placebo[1]. Paroxetine and benzodiazepines were also effective but poorly tolerated[1].

Mirtazapine, sertraline, fluoxetine, buspirone and agomelatine also looked effective and well tolerated, though the authors noted those findings rested on small sample sizes[1].

A 2025 network meta-analysis in European Archives of Psychiatry and Clinical Neuroscience widened the lens to 100 trials and 28,637 participants with GAD and other anxiety disorders[7]. The tricyclic clomipramine had the largest effect (HAM-A mean difference −7.70) but also the highest all-cause discontinuation (risk ratio 1.41)[7].

Of the 13 treatments that cleared that review's 2.5-point HAM-A threshold for a clinically relevant effect, 8 were at least as acceptable as placebo, including escitalopram, venlafaxine, pregabalin, diazepam and alprazolam[7]. The authors' summary was that efficacy and acceptability "do not always align"[7].

The same review rated silexan, an oral lavender-oil preparation, among the options with the best balance of benefit and side effects[7]. Evidence on other non-prescription products is reviewed in supplements for anxiety.

Which Medicines Ranked Best, by Anxiety Disorder

DisorderReviewEvidence baseBest balance of benefit and tolerabilityMain trade-off
Generalized anxiety disorderSlee et al., 201989 trials, 25,441 patientsDuloxetine, pregabalin, venlafaxine, escitalopramQuetiapine had the largest effect but was poorly tolerated
Anxiety disorders (mostly GAD)Müller et al., 2025100 trials, 28,637 participantsEscitalopram, venlafaxine, agomelatine, bromazepam, silexanClomipramine had the largest effect and the most dropouts
Panic disorderChawla et al., 202287 studies, 12,800 participantsSSRIs, especially sertraline and escitalopramBenzodiazepines ranked first for remission but raised adverse events
Social anxiety disorderMayo-Wilson et al., 2014101 trials, 13,164 participantsSSRIs and SNRIs (only drug class to beat pill placebo)Individual CBT had the largest effect of any intervention

Drugs each network meta-analysis identified as combining benefit with acceptable tolerability, adults[1][7][2][4]

1Rankings come from mostly short-term randomized trials; certainty of evidence in the panic disorder review was rated moderate to very low[2].

2In the 2025 review, 67 of the 100 trials enrolled people with GAD and 11 enrolled people with social anxiety disorder[7].

Sources

  • •The Lancet, 2019
  • •Eur Arch Psychiatry Clin Neurosci, 2025
  • •BMJ, 2022
  • •The Lancet Psychiatry, 2014

Best Medicine by Type of Anxiety Disorder

Generalized anxiety disorder

For generalized anxiety disorder, duloxetine and venlafaxine (SNRIs), escitalopram (an SSRI) and pregabalin had the best mix of benefit and tolerability in the 2019 Lancet review[1]. Escitalopram and venlafaxine also landed in the best-balanced group of the 2025 review[7].

Panic disorder

In the 2022 BMJ review of 87 studies and 12,800 adults with panic disorder, tricyclics, benzodiazepines, MAOIs, SSRIs and SNRIs all produced higher remission rates than placebo[2]. Benzodiazepines ranked first for remission (risk ratio 1.47; SUCRA 84.5%), and SSRIs ranked third (risk ratio 1.38)[2].

Benzodiazepines and tricyclics also raised the risk of adverse events by 76% and 79% over placebo, compared with 19% for SSRIs[2]. Weighing both outcomes, the authors concluded SSRIs offer high remission with a low risk of adverse events, with sertraline and escitalopram standing out[2].

Social anxiety disorder

A 2014 network meta-analysis of 101 trials and 13,164 adults with social anxiety disorder found MAOIs, benzodiazepines, SSRIs and SNRIs, and anticonvulsants all beat a waitlist[4]. Only SSRIs and SNRIs outperformed pill placebo (standardized mean difference −0.44)[4].

The same review found individual cognitive behavioral therapy (CBT) had the largest effect of any intervention and called it the best initial treatment, with SSRIs showing "the most consistent evidence of benefit" for people who decline therapy[4]. Trial details are in our social anxiety disorder treatments review.

Situational and performance anxiety

Beta-blockers are prescribed off-label for short-term anxiety symptoms, according to NIMH[8]. A 2025 meta-analysis in the Journal of Affective Disorders found no evidence that beta-blockers beat placebo or benzodiazepines for social phobia or panic disorder, even though prescribing for anxiety rose substantially between 2003 and 2018[9].

NIMH notes beta-blockers are generally not recommended for people with asthma or diabetes[8]. Situational anxiety is covered in more depth in performance anxiety.

Fastest Relief vs. Best Long-Term Option

Speed is where the drug classes differ most. Antidepressants, including SSRIs and SNRIs, usually take 4 to 8 weeks to work, according to NIMH[8]. Buspirone has to be taken daily for 3 to 4 weeks to reach full effect and does not work on an as-needed basis[8].

Benzodiazepines act quickly and are useful as needed for severe short-term anxiety, but taking them over long periods may lead to tolerance or dependence, so prescribers usually limit them to short courses and taper slowly[8].

In 2020, the FDA required an updated boxed warning on every benzodiazepine covering abuse, misuse, addiction, physical dependence and withdrawal reactions[3]. The agency said physical dependence can develop when benzodiazepines are taken steadily for several days to weeks, even as prescribed, and that stopping abruptly can cause withdrawal reactions including seizures[3].

That is the core trade-off behind the rankings. Benzodiazepines score near the top on short-term symptom relief[2][10], while SSRIs and SNRIs are slower to start but rank well on benefit and tolerability together[1][2].

Is Medication Better Than Therapy for Anxiety?

A 2015 meta-analysis of 234 trials with 37,333 patients with panic disorder, GAD or social anxiety disorder found larger average pre-post effect sizes for medications (Cohen's d 2.02) than for psychotherapies (1.22)[10]. Among drug classes, SNRIs had the largest (2.25), followed by benzodiazepines (2.15), SSRIs (2.09) and tricyclics (1.83)[10].

Pre-post effect sizes measure change from the start to the end of treatment and include any placebo response, so they are not head-to-head comparisons. In social anxiety disorder, where interventions were compared directly in a network, individual CBT had the largest effect[4].

Combining the two has the clearest support. A 2014 World Psychiatry meta-analysis of 52 trials with 3,623 patients found combined treatment outperformed an antidepressant alone (Hedges' g 0.43, number needed to treat 4.2)[5].

The advantage was significant for panic disorder (g 0.54) and obsessive-compulsive disorder (g 0.70) and fell just short of significance for social anxiety disorder (g 0.32)[5]. After adjusting for possible publication bias, the overall effect shrank to g 0.29[5].

The therapies with the most trial support are compared in therapy for anxiety.

Relapse within up to one year after switching to placebo vs. staying on an antidepressant that had worked for an anxiety disorder
36.4% vs. 16.4%

Pooled from 28 relapse-prevention trials with 5,233 patients. Prevalence varied widely between studies, largely because follow-up ranged from 8 to 52 weeks.

"discontinuation of antidepressant treatment results in higher relapse rates among responders compared with treatment continuation"

BMJ (Batelaan et al.)(2017) View Source

How Long Do People Stay on Anxiety Medication?

Relapse-prevention trials take people who have already improved on an antidepressant and randomly assign them to keep taking it or switch to placebo. Across 28 such trials with 5,233 patients, 36.4% of those switched to placebo relapsed during follow-up of up to one year, compared with 16.4% of those who continued[6].

Stopping roughly tripled the odds of relapse (odds ratio 3.11), and relapse came sooner[6]. The authors cautioned against reading the lack of data beyond one year as advice to stop at that point[6].

The 2019 GAD review added that a first drug failing "might not be a reason to abandon" medication, since several classes work[1]. Timelines and side effects for individual SSRIs are compared in SSRI for anxiety.

Frequently Asked Questions

Sources & References

  1. Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. The Lancet. Published 2019. Accessed October 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31793-8/fulltext [Link]
  2. Chawla N, Anothaisintawee T, Charoenrungrueangchai K, et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ. Published 2022. Accessed October 2026. https://www.bmj.com/content/376/bmj-2021-066084 [Link]
  3. U.S. Food and Drug Administration. FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. Published 2020. Accessed October 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class [Link]
  4. Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. The Lancet Psychiatry. Published 2014. Accessed October 2026. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(14)70329-3/fulltext [Link]
  5. Cuijpers P, Sijbrandij M, Koole SL, et al. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. Published 2014. Accessed October 2026. https://onlinelibrary.wiley.com/doi/10.1002/wps.20089 [Link]
  6. Batelaan NM, Bosman RC, Muntingh A, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. Published 2017. Accessed October 2026. https://www.bmj.com/content/358/bmj.j3927 [Link]
  7. Müller TJ, Künzi A, Heitlinger E, et al. Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders: a systematic review and network meta-analysis. European Archives of Psychiatry and Clinical Neuroscience. Published 2025. Accessed October 2026. https://link.springer.com/article/10.1007/s00406-025-02082-0 [Link]
  8. National Institute of Mental Health. Mental Health Medications. Published 2023. Accessed October 2026. https://www.nimh.nih.gov/health/topics/mental-health-medications [Link]
  9. Beta-blockers for the treatment of anxiety disorders: a systematic review and meta-analysis. Journal of Affective Disorders. Published 2025. Accessed October 2026. https://doi.org/10.1016/j.jad.2024.09.068 [Link]
  10. Bandelow B, Reitt M, Röver C, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. International Clinical Psychopharmacology. Published 2015. Accessed October 2026. https://doi.org/10.1097/YIC.0000000000000078 [Link]

Related Statistics